Clinical Trial Detail

NCT ID NCT02888743
Title Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors National Cancer Institute (NCI)
Indications

colorectal cancer

non-small cell lung carcinoma

Therapies

Durvalumab + Tremelimumab

Age Groups: senior adult

Additional content available in CKB BOOST